title: Induction of Potent Antigen-specific Cytotoxic T Cell Response by PLGA-nanoparticles Containing Antigen and TLR Agonist.
abstract: Previously we showed that biodegradable nanoparticles containing poly-IC or CpG oligodeoxynucleotide (ODN) together with ovalbumin (OVA) were efficient at inducing MHC-restricted presentation of OVA peptides in dendritic cells. The CTL-inducing activities of the nanoparticles were examined in the present study. Nanoparticles containing poly-IC or CpG ODN together with OVA were prepared using biodegradable polymer poly(D,L-lactic acid-co-glycolic acid), and then were opsonized with mouse IgG. The nanoparticles were injected into the tail vein of mice, and 7 days later the OVA-specific CTL activities were measured using an in vivo CTL assay. Immunization of mice with the nanoparticles containing poly-IC or CpG ODN together with OVA elicited potent OVA-specific CTL activity compared to those containing OVA only. In accordance with these results, nanoparticles containing poly-IC or CpG ODN together with OVA exerted potent antitumor activity in mice that were subcutaneously implanted with EG7.OVA tumor cells. These results show that encapsulation of poly-IC or CpG ODN together with antigen in biodegradable nanoparticles is an effective approach for the induction of potent antigen-specific CTL responses in vivo.
authors.affiliation: College of Pharmacy, Chungbuk National University, Cheongju 361-763, Korea.
authors.forename: Young-Ran
authors.initials: YR
authors.lastname: Lee
authors.forename: Young-Hee
authors.initials: YH
authors.lastname: Lee
authors.forename: Ki-Hyang
authors.initials: KH
authors.lastname: Kim
authors.forename: Sun-A
authors.initials: SA
authors.lastname: Im
authors.forename: Chong-Kil
authors.initials: CK
authors.lastname: Lee
keywords: Antitumor activity; CTL; CpG; Nanoparticle; PLGA; Poly-IC
references.citation: Immunol Rev. 2002 Oct;188:51-64
references.pmid: 12445281
references.citation: Immunology. 2006 Jan;117(1):78-88
references.pmid: 16423043
references.citation: J Pharm Sci. 1998 Nov;87(11):1421-7
references.pmid: 9811500
references.citation: J Immunol. 2011 Sep 1;187(5):2112-21
references.pmid: 21795597
references.citation: Immune Netw. 2011 Jun;11(3):163-8
references.pmid: 21860609
references.citation: Arch Pharm Res. 2010 Nov;33(11):1859-66
references.pmid: 21116790
references.citation: Int Immunopharmacol. 2011 Aug;11(8):985-91
references.pmid: 21354357
references.citation: Cell. 1988 Sep 9;54(6):777-85
references.pmid: 3261634
references.citation: Science. 1994 May 13;264(5161):961-5
references.pmid: 7513904
references.citation: Immunol Today. 1998 Aug;19(8):368-73
references.pmid: 9709505
references.citation: Annu Rev Immunol. 2001;19:47-64
references.pmid: 11244030
references.citation: Adv Drug Deliv Rev. 2003 Feb 24;55(3):329-47
references.pmid: 12628320
references.citation: Trends Cell Biol. 1995 Mar;5(3):105-9
references.pmid: 14732164
references.citation: Vaccine. 1999 Apr 9;17(15-16):1814-9
references.pmid: 10217578
references.citation: Vaccine. 2004 Jun 23;22(19):2406-12
references.pmid: 15193402
references.citation: Blood. 2005 May 15;105(10):3951-5
references.pmid: 15657176
references.citation: Nature. 1993 Jan 28;361(6410):359-62
references.pmid: 7678924
references.citation: Arch Pharm Res. 2007 Nov;30(11):1440-6
references.pmid: 18087813
references.citation: Nature. 1999 Mar 4;398(6722):77-80
references.pmid: 10078533